Accendra Health vs Henry Schein
ACH and HSIC side by side, both in professional and commercial equipment and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACH and HSIC compare
Henry Schein is the larger company, worth 493 times as much as Accendra Health ($9.6B against $19.5M).
Henry Schein grew revenue faster over the last twelve months (6.5% versus −3.3% for Accendra Health).
Henry Schein keeps more of each dollar of sales as profit, with a net margin of 3.0% compared with −11.4% at Accendra Health.
Henry Schein scores higher on the StockData Score (6 against 4 for Accendra Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACH | HSIC |
|---|---|---|
| Size and price | ||
| Market cap | $19.5M | $9.6B |
| Share price | $0.254 | $86.44 |
| Change, 1 year | −95.1% | 36.8% |
| Change, 5 years | −99.4% | 7.9% |
| Beta (5Y) | 1.46 | 0.56 |
| Employees | 6,500 | 25K |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.2× |
| P/S | 0.0× (better) | 0.7× |
| P/B | – | 3.1× |
| EV/EBITDA | 6.1× (better) | 13.5× |
| P/FCF | – | 16.9× |
| FCF yield | −1827% | 5.9% (better) |
| Fair value | $12.26 | $72.60 |
| Margin of safety | 97.9% (better) | −19.1% |
| Growth | ||
| Revenue growth (TTM) | −3.3% | 6.5% (better) |
| Revenue growth, 5Y average | −20.1% | 5.4% (better) |
| Net income growth (TTM) | – | 3.6% |
| EPS growth (TTM) | – | 10.3% |
| EPS growth, 5Y average | – | 3.0% |
| Profitability | ||
| Gross margin | 44.8% (better) | 31.3% |
| Operating margin | 1.1% | 5.0% (better) |
| Net margin | −11.4% | 3.0% (better) |
| FCF margin | −13.5% | 4.2% (better) |
| Return on equity | – | 12.2% |
| Return on invested capital | 1.6% | 8.1% (better) |
| Financial health | ||
| Debt / equity | – | 1.10 |
| Net debt / EBITDA | 5.99 | 3.28 (better) |
| Interest coverage | 0.2× | 4.3× (better) |
| Current ratio | 0.41 | 1.32 (better) |
| Altman Z-score | 0.30 | 2.77 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 7.6% |
| Shareholder yield | 0.00% | 7.6% (better) |
| Ownership | ||
| Held by institutions | 81.1% | 110% |
| Held by insiders | 21.0% | 18.0% |
| Insider net buying, 12 months | – | −$7.9M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 13.9% | 9.1% |
Go deeper
- ACH stock overview
- ACH income statement
- ACH valuation and score
- HSIC stock overview
- HSIC income statement
- HSIC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.